NOVEL PYRIDAZINES

• US 20200131151A1
• Filed: 10/25/2019
• Published: 04/30/2020
• Est. Priority Date: 10/29/2018
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: ROTH, Gerald Juergen, BRETSCHNEIDER, Tom, KUTTRUFF, Christian Andreas
• Granted Patent: US 11,104,665 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/501 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: C07D 237/22 Nitrogen and oxygen atoms
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to novel pyridazines, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of diseases and disorders mediated by Autotaxin.

Claims

1. A compound according to formula (I)

2. The compound of formula (I) according to claim 1, wherein A is selected from the group consisting of phenyl and pyridyl optionally substituted with one or two members of the group consisting of H, F₃CO—

, NC—

, F, Cl, Br, and H₃CO—

.

3. The compound of formula (I) according to claim 1, wherein A is phenyl, optionally substituted with one or two members of the group consisting of H, F₃CO—

, NC—

, F, Cl, Br, and H₃CO—

.

4. The compound of formula (I) according to claim 1, wherein A is pyridyl, optionally substituted with one or two members of the group consisting of H, F₃CO—

, NC—

, F, Cl, Br, and H₃CO—

.

5. The compound of formula (I) according to claim 1, wherein A is selected from the group consisting of

6. The compound of formula (I) according to claim 1, wherein A is selected from the group consisting of

7. The compound of formula (I) according to claim 1, wherein K is selected from the group consisting of

8. The compound of formula (I) according to claim 1, selected from the group consisting of

9. A pharmaceutically acceptable salt of a compound of formula (I) according to claim 1.

10. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 and one or more pharmaceutically acceptable excipients.

11. A method for the treatment or prevention of inflammatory airway diseases and fibrotic diseases comprising administering to a patient a compound of formula (I) according to claim 1.

12. A method for the treatment or prevention of idiopathic lung disease (IPF) and systemic sclerosis (SSc) comprising administering to a patient a compound of formula (I) according to claim 1.